Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04628494




Registration number
NCT04628494
Ethics application status
Date submitted
9/11/2020
Date registered
13/11/2020
Date last updated
5/11/2024

Titles & IDs
Public title
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL
Scientific title
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Secondary ID [1] 0 0
2020-003016-27
Secondary ID [2] 0 0
GCT3013-05
Universal Trial Number (UTN)
Trial acronym
EPCORE DLBCL-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diffuse Large B-cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Other - Epcoritamab
Treatment: Drugs - Investigator's Choice Chemotherapy

Experimental: Epcoritamab (GEN3013; DuoBody®CD3xCD20) - Epcoritamab will be administered in Cycles of 28 days until any of the discontinuation criteria is met

Active comparator: Investigator's choice of chemotherapy - R-GemOx will be administrated in Cycles of 28 days until maximum cycles completion or any of the discontinuation criteria is met

BR will be administrated in Cycles of 21 days until maximum cycles completion or any of the discontinuation criteria is met


Treatment: Other: Epcoritamab
Following mandatory pre-medication subject will be administered epcoritamab as a subcutaneous injection.

Treatment: Drugs: Investigator's Choice Chemotherapy
Following mandatory pre-medication subject will be administered intravenously either BR or R-GemOx.
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [2] 0 0
Overall Response Rate (ORR)
Timepoint [2] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [3] 0 0
Complete Response (CR)
Timepoint [3] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [4] 0 0
Duration of Response (DOR)
Timepoint [4] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [5] 0 0
Time to Response (TTR)
Timepoint [5] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [6] 0 0
Rate and duration of minimal residual disease (MRD) negative status
Timepoint [6] 0 0
up to 5 years after randomization of the last patient
Secondary outcome [7] 0 0
Time to next anti-lymphoma therapy (TTNT)
Timepoint [7] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [8] 0 0
Incidence and severity of adverse events (AEs)
Timepoint [8] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [9] 0 0
Incidence and severity of changes in laboratory values
Timepoint [9] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [10] 0 0
Incidence of dose interruptions and delays
Timepoint [10] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [11] 0 0
Anti-epcoritamab antibody response
Timepoint [11] 0 0
throughout the study and up to 5 years following the last patient first dose
Secondary outcome [12] 0 0
Changes in lymphoma symptoms as measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)
Timepoint [12] 0 0
throughout the study and up to 5 years following the last patient first dose

Eligibility
Key inclusion criteria
Main

1. Relapsed or refractory disease and previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since lymphoma diagnosis
2. One of the confirmed histologies below with CD20-positivity:

1. DLBCL, NOS, including de novo or histologically transformed from FL
2. "Double-hit" or "triple-hit" DLBCL (technically classified in WHO 2016 as HGBCL, with MYC and BCL2 and/or BCL6 translocations), including de novo or histologically transformed from FL
3. FL Grade 3B
4. T-cell/histiocyte-rich large B-cell lymphoma
3. ECOG PS score of 0-2
4. Failed previous HDT-ASCT or not eligible for HDT-ASCT at screening
5. Patients must have detectable disease by PET scan and measurable by CT scan or MRI
6. Acceptable renal and liver function
7. Life expectancy >2 months on SOC treatment

Main
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Primary Central Nervous System (CNS) tumor or known CNS involvement
2. Any prior therapy with a bispecific antibody targeting CD3 and CD20
3. Major surgery within 4 weeks prior to randomization
4. Chemotherapy and other non-investigational antineoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to randomization
5. Any investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to randomization
6. ASCT within 100 days of randomization
7. Treatment with CAR-T therapy within 100 days prior to randomization
8. Seizure disorder requiring anti-epileptic therapy
9. Clinically significant cardiac disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/01/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/04/2028
Actual
Sample size
Target
552
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [3] 0 0
Peninsula Private Hospital Clinical Trials Unit - Frankston
Recruitment hospital [4] 0 0
Icon Cancer Centre Corporate Office - South Brisbane
Recruitment hospital [5] 0 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [6] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
- Bedford Park
Recruitment postcode(s) [2] 0 0
- Concord
Recruitment postcode(s) [3] 0 0
- Frankston
Recruitment postcode(s) [4] 0 0
- South Brisbane
Recruitment postcode(s) [5] 0 0
- Waratah
Recruitment postcode(s) [6] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Indiana
Country [2] 0 0
United States of America
State/province [2] 0 0
Kentucky
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
North Carolina
Country [5] 0 0
United States of America
State/province [5] 0 0
Ohio
Country [6] 0 0
United States of America
State/province [6] 0 0
Utah
Country [7] 0 0
Austria
State/province [7] 0 0
Linz
Country [8] 0 0
Austria
State/province [8] 0 0
Salzburg
Country [9] 0 0
Belgium
State/province [9] 0 0
Antwerp
Country [10] 0 0
Belgium
State/province [10] 0 0
Brugge
Country [11] 0 0
Belgium
State/province [11] 0 0
Brussels
Country [12] 0 0
Belgium
State/province [12] 0 0
Gent
Country [13] 0 0
Belgium
State/province [13] 0 0
Jette
Country [14] 0 0
Belgium
State/province [14] 0 0
La Louvière
Country [15] 0 0
Belgium
State/province [15] 0 0
Leuven
Country [16] 0 0
Belgium
State/province [16] 0 0
Sint-Niklaas
Country [17] 0 0
Belgium
State/province [17] 0 0
Turnhout
Country [18] 0 0
Canada
State/province [18] 0 0
Québec City
Country [19] 0 0
China
State/province [19] 0 0
Baoding
Country [20] 0 0
China
State/province [20] 0 0
Beijing
Country [21] 0 0
China
State/province [21] 0 0
Changchun
Country [22] 0 0
China
State/province [22] 0 0
Chengdu
Country [23] 0 0
China
State/province [23] 0 0
Dalian
Country [24] 0 0
China
State/province [24] 0 0
Guangdong
Country [25] 0 0
China
State/province [25] 0 0
Guangxi
Country [26] 0 0
China
State/province [26] 0 0
Hangzhou
Country [27] 0 0
China
State/province [27] 0 0
Hubei
Country [28] 0 0
China
State/province [28] 0 0
Hunan
Country [29] 0 0
China
State/province [29] 0 0
Nanchang
Country [30] 0 0
China
State/province [30] 0 0
Qingdao
Country [31] 0 0
China
State/province [31] 0 0
Shanxi
Country [32] 0 0
China
State/province [32] 0 0
Shenyang
Country [33] 0 0
China
State/province [33] 0 0
Shenzhen
Country [34] 0 0
China
State/province [34] 0 0
Suzhou
Country [35] 0 0
China
State/province [35] 0 0
Tianjin
Country [36] 0 0
China
State/province [36] 0 0
Wuhan
Country [37] 0 0
China
State/province [37] 0 0
Yantai
Country [38] 0 0
China
State/province [38] 0 0
Zhengzhou
Country [39] 0 0
China
State/province [39] 0 0
Zhenjiang
Country [40] 0 0
Denmark
State/province [40] 0 0
Aalborg
Country [41] 0 0
Denmark
State/province [41] 0 0
Aarhus
Country [42] 0 0
Denmark
State/province [42] 0 0
Roskilde
Country [43] 0 0
Denmark
State/province [43] 0 0
Vejle
Country [44] 0 0
Finland
State/province [44] 0 0
Helsinki
Country [45] 0 0
Finland
State/province [45] 0 0
Oulu
Country [46] 0 0
France
State/province [46] 0 0
Amiens
Country [47] 0 0
France
State/province [47] 0 0
Bayonne
Country [48] 0 0
France
State/province [48] 0 0
Brest
Country [49] 0 0
France
State/province [49] 0 0
Caen
Country [50] 0 0
France
State/province [50] 0 0
La Rochelle
Country [51] 0 0
France
State/province [51] 0 0
Limoges
Country [52] 0 0
France
State/province [52] 0 0
Lyon
Country [53] 0 0
France
State/province [53] 0 0
Marseille
Country [54] 0 0
France
State/province [54] 0 0
Nantes
Country [55] 0 0
France
State/province [55] 0 0
Nice
Country [56] 0 0
France
State/province [56] 0 0
Paris
Country [57] 0 0
France
State/province [57] 0 0
Pessac
Country [58] 0 0
France
State/province [58] 0 0
Pierre-Bénite
Country [59] 0 0
France
State/province [59] 0 0
Poitiers
Country [60] 0 0
France
State/province [60] 0 0
Pontoise
Country [61] 0 0
France
State/province [61] 0 0
Quimper
Country [62] 0 0
France
State/province [62] 0 0
Rouen
Country [63] 0 0
France
State/province [63] 0 0
Tours
Country [64] 0 0
Germany
State/province [64] 0 0
Cologne
Country [65] 0 0
Germany
State/province [65] 0 0
Essen
Country [66] 0 0
Germany
State/province [66] 0 0
Kiel
Country [67] 0 0
Germany
State/province [67] 0 0
Würzburg
Country [68] 0 0
Hungary
State/province [68] 0 0
Budapest
Country [69] 0 0
Hungary
State/province [69] 0 0
Debrecen
Country [70] 0 0
Hungary
State/province [70] 0 0
Eger
Country [71] 0 0
Hungary
State/province [71] 0 0
Gyor
Country [72] 0 0
Hungary
State/province [72] 0 0
Nyiregyhaza
Country [73] 0 0
Hungary
State/province [73] 0 0
Pécs
Country [74] 0 0
Hungary
State/province [74] 0 0
Szeged
Country [75] 0 0
Hungary
State/province [75] 0 0
Szekesfehervar
Country [76] 0 0
Israel
State/province [76] 0 0
Haifa
Country [77] 0 0
Israel
State/province [77] 0 0
Jerusalem
Country [78] 0 0
Israel
State/province [78] 0 0
Tel Aviv
Country [79] 0 0
Italy
State/province [79] 0 0
Bari
Country [80] 0 0
Italy
State/province [80] 0 0
Bergamo
Country [81] 0 0
Italy
State/province [81] 0 0
Brescia
Country [82] 0 0
Italy
State/province [82] 0 0
Meldola
Country [83] 0 0
Italy
State/province [83] 0 0
Milan
Country [84] 0 0
Italy
State/province [84] 0 0
Novara
Country [85] 0 0
Italy
State/province [85] 0 0
Pavia
Country [86] 0 0
Italy
State/province [86] 0 0
Ravenna
Country [87] 0 0
Italy
State/province [87] 0 0
Rome
Country [88] 0 0
Italy
State/province [88] 0 0
San Giovanni Rotondo
Country [89] 0 0
Italy
State/province [89] 0 0
Trieste
Country [90] 0 0
Italy
State/province [90] 0 0
Venezia
Country [91] 0 0
Japan
State/province [91] 0 0
Fukuoka
Country [92] 0 0
Japan
State/province [92] 0 0
Fukushima
Country [93] 0 0
Japan
State/province [93] 0 0
Fukuyama
Country [94] 0 0
Japan
State/province [94] 0 0
Hokkaido
Country [95] 0 0
Japan
State/province [95] 0 0
Kashiwa
Country [96] 0 0
Japan
State/province [96] 0 0
Kyoto
Country [97] 0 0
Japan
State/province [97] 0 0
Matsuyama
Country [98] 0 0
Japan
State/province [98] 0 0
Mie
Country [99] 0 0
Japan
State/province [99] 0 0
Nagoya
Country [100] 0 0
Japan
State/province [100] 0 0
Okayama
Country [101] 0 0
Japan
State/province [101] 0 0
Sendai
Country [102] 0 0
Japan
State/province [102] 0 0
Tokyo
Country [103] 0 0
Japan
State/province [103] 0 0
Toyoake
Country [104] 0 0
Japan
State/province [104] 0 0
Yamagata
Country [105] 0 0
Japan
State/province [105] 0 0
Osaka-sayama
Country [106] 0 0
Korea, Republic of
State/province [106] 0 0
Busan
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Daegu
Country [108] 0 0
Korea, Republic of
State/province [108] 0 0
Geumam
Country [109] 0 0
Korea, Republic of
State/province [109] 0 0
Seoul
Country [110] 0 0
Korea, Republic of
State/province [110] 0 0
Ulsan
Country [111] 0 0
Netherlands
State/province [111] 0 0
Arnhem
Country [112] 0 0
Netherlands
State/province [112] 0 0
Breda
Country [113] 0 0
Netherlands
State/province [113] 0 0
Dordrecht
Country [114] 0 0
Netherlands
State/province [114] 0 0
Goes
Country [115] 0 0
Netherlands
State/province [115] 0 0
Roosendaal
Country [116] 0 0
Netherlands
State/province [116] 0 0
Rotterdam
Country [117] 0 0
Norway
State/province [117] 0 0
Oslo
Country [118] 0 0
Norway
State/province [118] 0 0
Trondheim
Country [119] 0 0
Poland
State/province [119] 0 0
Gdansk
Country [120] 0 0
Poland
State/province [120] 0 0
Katowice
Country [121] 0 0
Poland
State/province [121] 0 0
Kraków
Country [122] 0 0
Poland
State/province [122] 0 0
Skorzewo
Country [123] 0 0
Poland
State/province [123] 0 0
Wroclaw
Country [124] 0 0
Poland
State/province [124] 0 0
Lódz
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Kazan
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Leningrad
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Moscow
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Nizhny Novgorod
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Saint Petersburg
Country [130] 0 0
Singapore
State/province [130] 0 0
Kent Ridge
Country [131] 0 0
Singapore
State/province [131] 0 0
Singapore
Country [132] 0 0
Spain
State/province [132] 0 0
Badalona
Country [133] 0 0
Spain
State/province [133] 0 0
Barcelona
Country [134] 0 0
Spain
State/province [134] 0 0
Cadiz
Country [135] 0 0
Spain
State/province [135] 0 0
Cáceres,
Country [136] 0 0
Spain
State/province [136] 0 0
Cáceres
Country [137] 0 0
Spain
State/province [137] 0 0
Córdoba
Country [138] 0 0
Spain
State/province [138] 0 0
Lleida
Country [139] 0 0
Spain
State/province [139] 0 0
Madrid
Country [140] 0 0
Spain
State/province [140] 0 0
Salamanca
Country [141] 0 0
Spain
State/province [141] 0 0
Santander
Country [142] 0 0
Spain
State/province [142] 0 0
Sevilla
Country [143] 0 0
Sweden
State/province [143] 0 0
Stockholm
Country [144] 0 0
Taiwan
State/province [144] 0 0
Kaohsiung
Country [145] 0 0
Taiwan
State/province [145] 0 0
Tainan
Country [146] 0 0
Taiwan
State/province [146] 0 0
Taipei
Country [147] 0 0
Turkey
State/province [147] 0 0
Ankara
Country [148] 0 0
Turkey
State/province [148] 0 0
Istanbul
Country [149] 0 0
Turkey
State/province [149] 0 0
Izmir
Country [150] 0 0
Turkey
State/province [150] 0 0
Tekirdag
Country [151] 0 0
Turkey
State/province [151] 0 0
Trabzon
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Birmingham
Country [153] 0 0
United Kingdom
State/province [153] 0 0
London
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Norwich
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Nottingham
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Plymouth
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Southampton
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Sutton
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Truro

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Genmab
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
AbbVie
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with diffuse large B-cell lymphoma (DLBCL) that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin \[R-GemOx\], or bendamustine + rituximab \[BR\]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT).

Epcoritamab will be injected under the skin. Investigator's choice chemotherapy will be given intravenously.

Trial details include:

* The trial duration will be up to 5 years.
* All trial participants have a 21-day screening period, a treatment period, and a follow-up period that continues until death.
* The estimated trial duration for an individual subject depends upon the treatment arm assigned:

* Participants who receive epcoritamab will have 28-day treatment cycles. Epcoritamab will be given once weekly for the first 3 months, then every other week for 6 months, then every 28 days until lymphoma progression or unacceptable adverse events.
* Participants who receive investigator's choice (standard of care) chemotherapy will receive treatments either:

* R-GemOx: On Day 1 (or Day 1 \& Day 2), and Day 15 (or Day 15 \& Day 16) every 28 days, for up to 4 months; or
* BR: On Day 1 and Day 2 every 3 weeks for up to 4.5 months.
Trial website
https://clinicaltrials.gov/study/NCT04628494
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04628494